In the News

« Back

PhotoniCare’s TOMi Scope [OtoSight Middle Ear Scope] takes Top Prize at SPIE and Photonics Media Prism Awards

TOMi Scope [OtoSight Middle Ear Scope] allows healthcare providers, for the first time ever, to non-invasively view fluid directly in the middle ear, even in the presence of wax build-up.

CHAMPAIGN, Ill.–(BUSINESS WIRE)–PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing healthcare providers with better diagnostic tools, today announced the company’s TOMi™ Scope [OtoSight Middle Ear Scope] was awarded best healthcare product at the 12th Annual Prism Awards in San Francisco. The Prism Awards is an annual international competition that honors the best new optics and photonics products on the market.

Since 2008, SPIE, along with media partner Photonics Media, has presented awards to companies and individuals that are creating products that make a difference, solve problems, and improve life through photonics. The Prism Awards reflect the exponential growth, exciting developments, and rich technical innovations across photonics and photonics-enabled industries.

PhotoniCare took home the top prize in the healthcare category for the TOMi Scope [OtoSight Middle Ear Scope]. The 510(k)-cleared TOMi Scope [OtoSight Middle Ear Scope] uses an advanced light-based technology to see through the eardrum. For the first time, healthcare providers can view a high-resolution depth image on-screen to directly visualize fluid and fluid density in the middle ear. Middle ear infections affect more than 80% of children and are misdiagnosed up to 50% of the time using the current gold standard, examination via otoscope. In addition, they are the leading cause of hearing loss, surgery and antibiotic use, especially in children. Children can suffer from recurring ear infections for six to 12 months before they are referred to an ENT specialist, and are often prescribed increasingly potent antibiotics during this time. More than one million tube surgeries are performed in the U.S. alone every year. TOMi Scope’s [OtoSight Middle Ear Scope] advanced light-based technology has the potential to dramatically alter the way children with ear problems are evaluated and treated.

Present to accept the award included Ryan Shelton, Ph.D., CEO & Co-founder; Stephen Boppart, M.D., Ph.D., CMO and Co-founder; Ryan Nolan, M.Eng., CCRP, VP of Clinical Operations and Co-founder; and Wei Kang, Director of R&D.

“It is such a huge honor to be recognized with this prestigious industry award for best healthcare product in 2020, and we’d like to thank SPIE and Photonics Media for sponsoring this incredible opportunity,” said Shelton. “Our team is working hard to provide better options to millions of patients who suffer from middle ear infections. Following our recent 510(k) clearance from the FDA, we cannot wait to see how the TOMi Scope [OtoSight Middle Ear Scope] impacts the standard of care for this incredibly common disease.

This year’s awards covered nine categories including healthcare, security and transportation to name a few. SPIE received over 105 applications from 18 countries for this year’s round of PRISM awards. Finalists were ultimately selected by a panel of international judges that included leaders from both the technology commercialization and funding sectors.

About PhotoniCare

Founded in 2013, PhotoniCare’s mission is to revolutionize healthcare by providing healthcare providers with better diagnostic tools, starting with the TOMi Scope™ [OtoSight Middle Ear Scope], the first and only otoscope to provide non-invasive imaging of the middle ear using a novel application of Optical Coherence Tomography (OCT) to directly visualize and characterize fluid in the middle ear, a necessity for

the diagnosis of middle ear infections. PhotoniCare has developed a patented imaging platform technology that provides growth opportunities beyond otology (study of the ear). Peer-reviewed studies show that the same handheld OCT technology can be used to image other areas, such as the anterior and posterior segments of the eye, the skin, and in the mouth.

For more information visit and follow us on Twitter @PhotoniCare, LinkedIn @PhotoniCare, Facebook @PhotoniCare, and Instagram @PhotoniCare.

Related News

  • PhotoniCare Appoints Former Welch Allyn CEO Steve Meyer to Advisory Board.

    Reports show that each year over 9-million children are diagnosed… Read More

  • Photonicare ISO 13485 Certification

    PhotoniCare Announces ISO 13485:2016 Certification

    Champaign, Ill. – December 20, 2021 – PhotoniCare, Inc.—a company… Read More

  • PhotoniCare CEO, Ryan Shelton, Wins NWA Pitch Competition

    The Northwest Arkansas Tech Summit declared Ryan Shelton, CEO and… Read More